Health-Related Quality of Life with Sacituzumab Govitecan in HR+/HER2− Metastatic Breast Cancer in the Phase III TROPiCS-02 Trial

    April 2024 in “ The Oncologist ”
    Hope S. Rugo, Peter Schmid, Sara M. Tolaney … Javier Cortés
    Studysummary This study found that sacituzumab govitecan improved health-related quality of life in most areas for patients with HR+/HER2− metastatic breast cancer compared to chemotherapy, except for increased diarrhea, supporting its use as a treatment option.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on academic.oup.com →
    Discuss this study in the Community →